A randomized, double-blind, placebo-controlled Phase II extended safety study of two Invisible Condom formulations in Cameroonian women.
BACKGROUND
Invisible Condom gel formulations being developed as microbicides to prevent the sexual transmission of HIV are advancing through the phases of clinical trials. The objectives of this study were to evaluate, after 8 weeks of vaginal application, the extended safety and acceptability of two Invisible Condom vaginal gel formulations: (i) the polymer alone and (ii) the polymer containing sodium lauryl sulfate (SLS) compared to placebo.


METHODS
This study is a randomized, doubled-blind, placebo-controlled Phase II extended safety study in healthy sexually active women from Yaoundé, Cameroon. Women were randomized into three gel arms: (i) placebo, (ii) polymer alone and (iii) polymer/SLS. Women applied gel intravaginally twice daily for 8 weeks.


RESULTS
A total of 194 sexually active women applied placebo (n=41), polymer alone (n=76) and polymer/SLS (n=77). Invisible Condom gel formulations were well tolerated with no reported serious adverse events. The majority of reported adverse events were mild or moderate and mostly similar in all three arms, except for pelvic pain that was 10% higher in the polymer and polymer/SLS arms compared to placebo. Colposcopy showed neither genital ulceration nor mucosal lesions. Nugent score, H(2)O(2)-producing lactobacilli and vaginal pH were not affected by the study products. The gel formulations and applicator were generally acceptable and comfortable.


CONCLUSIONS
This extended safety study showed that the Invisible Condom gel formulations and applicator were well tolerated and acceptable when applied intravaginally twice daily for 8 weeks. Thus, further phases of clinical development of Invisible Condom as a potential microbicide to prevent sexual transmission of HIV are warranted.
Mbopi-Keou
Francois-Xavier
FX
Laboratoire de Santé Hygiène Mobile, Ministry of Public Health and Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Yaoundé, Cameroon.
Trottier
Sylvie
S
Omar
Rabeea F
RF
Nkele
Ngoh N
NN
Fokoua
Séraphin
S
Mbu
Enow R
ER
Domingo
Marc-Christian
MC
Giguère
Jean-Francois
JF
Piret
Jocelyne
J
Mwatha
Anthony
A
Mâsse
Benoît
B
Bergeron
Michel G
MG
D000282:Administration, Intravaginal; D000293:Adolescent; D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage* / Q000009:adverse effects*; D002163:Cameroon; D004311:Double-Blind Method; D005260:Female; D015658:HIV Infections / Q000517:prevention & control; D006801:Humans; D008875:Middle Aged; D010349:Patient Compliance; D017060:Patient Satisfaction; D018579:Patient Selection; D011108:Polymers / Q000008:administration & dosage / Q000009:adverse effects; D014622:Vaginal Creams, Foams, and Jellies / Q000008:administration & dosage / Q000009:adverse effects
D019380:Anti-HIV Agents; D000891:Anti-Infective Agents, Local; D011108:Polymers; D014622:Vaginal Creams, Foams, and Jellies